Protocol 5 - In this protocol, Norton reviews the pathophysiology of fetal aneuploidy and the wide range of tests for it. Included are perspectives on cell-free DNA testing, first-trimester combined screening, nuchal translucency (NT) sonography, and pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG), as well as quad marker screening in the second trimester in appropriate cases, and combined first- and second-trimester screening.
Trisomies 21, 18, and 13 are the most common autosomal trisomies. Triploidy and deletions and duplications of portions of chromosomes also occur. With the advent of chromosomal microarray analysis, it is now possible to identify submicroscopic abnormalities associated with significant genetic diseases.
Key Messages
Adverse pregnancy outcomes linked to midlife cardiovascular disease risk
September 11th 2024In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Nipocalimab shows promise in preventing hemolytic disease of the fetus and newborn
August 21st 2024The investigational drug could prevent the rare fetal disease HDFN (hemolytic disease of the fetus and newborn) by stopping harmful antibodies from transferring through the placenta during pregnancy.
Read More